Implications of Clinical Risk Phenotypes on the Management and Natural History of Atrial Fibrillation: A Report From the GLORIA-AF

被引:8
|
作者
Romiti, Giulio Francesco [1 ,2 ,3 ]
Proietti, Marco [4 ,5 ]
Corica, Bernadette [1 ,2 ,3 ]
Bonini, Niccolo [1 ,2 ,6 ]
Boriani, Giuseppe [6 ]
Huisman, Menno V. [7 ]
Lip, Gregory Y. H. [1 ,2 ,8 ]
机构
[1] Liverpool John Moores Univ, Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England
[2] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[3] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[5] IRCCS Ist Clin Sci Maugeri, Div Subacute Care, Milan, Italy
[6] Univ Modena & Reggio Emilia, Policlin Modena, Div Cardiol, Dept Biomed Metab & Neural Sci, Modena, Italy
[7] Leiden Univ, Dept Thrombosis & Hemostasis, Med Ctr, Leiden, Netherlands
[8] Aalborg Univ, Danish Ctr Clin Hlth Serv Res, Dept Clin Med, Aalborg, Denmark
来源
关键词
anticoagulation; atrial fibrillation; clinical complexity; elderly individuals; outcomes; EUROBSERVATIONAL RESEARCH-PROGRAM; ANTICOAGULATION; STROKE; IMPACT; BARRIERS; OUTCOMES; PATHWAY; CARE;
D O I
10.1161/JAHA.123.030565
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Clinical risk factors are common among patients with atrial fibrillation (AF), but there are still limited data on their association with oral anticoagulant (OAC) treatment patterns and major outcomes. We aim to analyze the association between clinical risk phenotypes on AF treatment patterns and the risk of major outcomes. METHODS AND RESULTS: The GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation) phase 2 and 3 registries enrolled patients with a recent diagnosis of AF between 2011 and 2016. We defined 4 features of clinical risk among patients with CHA(2)DS(2)-VASc >= 2: elderly individuals (aged >= 80 years), chronic kidney disease (estimated glomerular filtration rate <45 mL/min), history of stroke, and history of bleeding. We analyzed the odds of receiving OAC and the risk of OAC discontinuation and adverse events at follow-up according to specific combinations and cumulative burden of these features. Primary outcome was the composite of all-cause death, thromboembolism, and major bleeding. Among 28 891 (mean +/- SD age, 70.1 +/- 10.5 years; 45.5% women) patients included, 10 797 (37.3%) had at least 1 clinical risk feature. OAC use was lower among patients in the elderly group (odds ratio [OR], 0.85 [95% CI, 0.75-0.96]), those with history of both stroke and bleeding (OR, 0.45 [95% CI, 0.35-0.56]), and those with multiple features (OR, 0.71 [95% CI, 0.62-0.82]). Increasing burden of clinical risk features was associated with OAC discontinuation, with highest magnitude in those with >= 3 features (hazard ratio [HR], 1.68 [95% CI, 1.31-2.15]). Groups with increasingly complex clinical risk phenotypes were associated with the occurrence of the primary composite outcome, with the highest figures observed for groups with a history of both stroke and bleeding (adjusted HR, 2.36 [95% CI, 1.83-3.04]) and multiple features (adjusted HR, 2.86 [95% CI, 2.52-3.25]). CONCLUSIONS: In patients with AF, clinical risk phenotypes are multifaceted and heterogenous, and they are associated with differences in stroke prevention and worse prognosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Impact of chronic obstructive pulmonary disease in patients with atrial fibrillation: an analysis from the GLORIA-AF registry
    Romiti, Giulio Francesco
    Corica, Bernadette
    Mei, Davide Antonio
    Frost, Frederick
    Bisson, Arnaud
    Boriani, Giuseppe
    Bucci, Tommaso
    Olshansky, Brian
    Chao, Tze-Fan
    Huisman, Menno, V
    Proietti, Marco
    Lip, Gregory Y. H.
    EUROPACE, 2023, 26 (01):
  • [22] Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry
    Mazurek, Michal
    Huisman, Menno V.
    Rothman, Kenneth J.
    Paquette, Miney
    Teutsch, Christine
    Diener, Hans-Christoph
    Dubner, Sergio J.
    Halperin, Jonathan L.
    Ma, Chang Sheng
    Zint, Kristina
    Elsaesser, Amelie
    Lu, Shihai
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (12) : 2376 - 2388
  • [23] Long-term risks and benefits of oral anticoagulation in atrial fibrillation patients with cancer: A report from the GLORIA-AF registry
    Li, Meng
    Huang, Bi
    Lam, Steven Ho Man
    Ishiguchi, Hironori
    Liu, Yang
    Olshansky, Brian
    Huisman, Menno V.
    Chao, Tze-Fan
    Lip, Gregory Y. H.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2025, 55 (02)
  • [24] Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
    Gregory Y. H. Lip
    Agnieszka Kotalczyk
    Christine Teutsch
    Hans-Christoph Diener
    Sergio J. Dubner
    Jonathan L. Halperin
    Chang-Sheng Ma
    Kenneth J. Rothman
    Sabrina Marler
    Venkatesh Kumar Gurusamy
    Menno V. Huisman
    Clinical Research in Cardiology, 2022, 111 : 560 - 573
  • [25] Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry
    Ma, Changsheng
    Riou Franca, Lionel
    Lu, Shihai
    Diener, Hans-Christoph
    Dubner, Sergio J.
    Halperin, Jonathan L.
    Li, Qiang
    Paquette, Miney
    Teutsch, Christine
    Huisman, Menno V.
    Lip, Gregory Y. H.
    Rothman, Kenneth J.
    JOURNAL OF ARRHYTHMIA, 2020, 36 (03) : 408 - 416
  • [26] Machine learning for outcome prediction in patients with non-valvular atrial fibrillation from the GLORIA-AF registry
    Joddrell, Martha
    El-Bouri, Wahbi
    Harrison, Stephanie L.
    Huisman, Menno V.
    Lip, Gregory Y. H.
    Zheng, Yalin
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [27] Patterns of pharmacological treatment in patients with atrial fibrillation: an analysis from the prospective GLORIA-AF Registry Phase III
    Corica, Bernadette
    Romiti, Giulio Francesco
    Boriani, Giuseppe
    Olshansky, Brian
    Chao, Tze-Fan
    Huisman, Menno V.
    Proietti, Marco
    Lip, Gregory Y. H.
    GLORIA AF Investigators
    BMC MEDICINE, 2025, 23 (01):
  • [28] Use of antithrombotic therapy in patients with atrial fibrillation and prior stroke: insights from the global GLORIA-AF registry
    Lip, G. Y. H.
    Halperin, J. L.
    Diener, H. C.
    Dubner, S. J.
    Ma, C. S.
    Rothman, K. J.
    Zint, K.
    Elsaesser, A.
    Paquette, M.
    Huisman, M. V.
    EUROPEAN HEART JOURNAL, 2015, 36 : 243 - 243
  • [29] Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program
    Mazurek, Michal
    Huisman, Menno V.
    Rothman, Kenneth J.
    Paquette, Miney
    Teutsch, Christine
    Diener, Hans-Christoph
    Dubner, Sergio J.
    Halperin, Jonathan L.
    Zint, Kristina
    Franca, Lionel Riou
    Lu, Shihai
    Lip, Gregory Y. H.
    AMERICAN JOURNAL OF MEDICINE, 2018, 131 (08): : 945 - +
  • [30] Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program
    Beier, Lea
    Lu, Shihai
    Franca, Lionel Riou
    Marler, Sabrina
    Lip, Gregory Y. H.
    Huisman, Menno, V
    Teutsch, Christine
    Halperin, Jonathan L.
    Zint, Kristina
    Diener, Hans-Christoph
    Baker, Laurie
    Ma, Chang-Sheng
    Paquette, Miney
    Bartels, Dorothee B.
    Dubner, Sergio J.
    Lyrer, Philippe
    Senges, Jochen
    Rothman, Kenneth J.
    PLOS ONE, 2022, 17 (10):